A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study

@article{Cooper2009ACC,
  title={A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study},
  author={Garth J S Cooper and Alistair A. Young and Greg D Gamble and Christopher Occleshaw and Ajith Munasinghe Dissanayake and Brett R. Cowan and Dianne Heather Brunton and Jeffrey R. Baker and Anthony R. J. Phillips and Christopher Miles Frampton and Sally D Poppitt and Robert Neil Doughty},
  journal={Diabetologia},
  year={2009},
  volume={52},
  pages={715-722}
}
AbstractAims/hypothesisCu(II)-selective chelation with trientine ameliorates cardiovascular and renal disease in a model of diabetes in rats. Here, we tested the hypothesis that Cu(II)-selective chelation might improve left ventricular hypertrophy (LVH) in type 2 diabetic patients.MethodsWe performed a 12 month randomised placebo-controlled study of the effects of treatment with the Cu(II)-selective chelator trientine (triethylenetetramine dihydrochloride, 600 mg given orally twice daily) on… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson’s disease

R Siegemund, J Lößner, K Günther, HJ Kühn, H Bachmann
  • Acta Neurol Scand
  • 1991
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL